BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes GlobeNewswire January 07, 2026 Decision ensures continued patient access to VENDAJE(R) and VENDAJE AC(R) POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization […]